The Global Colorectal Cancer Market Size will gain traction due to the factors such as technological advancements for developing therapies that would be effective in treating this type of cancer.

Colorectal cancer starts from colon, and is also referred as colon cancer. The cancer cells grow in the inner lining of colon or rectum and these cells are known as polyps. Generally, there are five types of colon cancer namely; Adenocarcinomas, carcinoid tumours, gastrointestinal stromal tumours, lymphomas, and sarcomas.  Adenocarcinomas is the most common type of colon cancer that makes up 96% of total colon cancer. The colorectal cancer spreads into lymph nodes that can be treated with surgical treatment followed by chemotherapy. Colorectal cancer is characterised by bleeding from back passage, losing weight, and pain in your abdomen or back passage. Approximately, 50,000 people die due to this disease every year.

According to American Society of Clinical Oncology (ASCO), colorectal is the fourth most common type of cancer in the U.S. In 2017, the number of people suffering from colorectal cancer were 135, 430 adults in the U.S.  

Technological advancements in the therapies like chemotherapy to boost the colorectal cancer market.

The colorectal cancer market is primarily driven by the increasing adoption of western diets globally. These diets contain high fats and low fibres leading to the formation of polyps in the colon or rectum. On the other hand, the increasing awareness for treating colorectal cancer by chemotherapy and immunotherapy would also propel the industry growth during the forecast period. While, rise in the aging population, and increasing awareness of consumers in the developing countries will also boost the colorectal market.

However, higher cost of the available treatments, less awareness for ongoing screening test of drugs, and expiring drug patents would impede the colorectal cancer market growth during the forecast period.

Global Colorectal Cancer Market Taxonomy

The colorectal cancer market is segmented on the basis of therapy, drug, diagnostics and geography.

On the basis of therapy, the global colorectal cancer market size is segmented as:

• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Surgery
• Others

On the basis of therapy, the global colorectal cancer market size is segmented as:

• Bevacizumab (Avastin)
• Cetuximab (Erbitux)
• Panitumumab (Vectibix)
• Regoraferin (Stivarga)
• Ziv-Aflibrcept (Zaltrap)
• TAS-10 (Lonsurf)
• Others

On the basis of therapy, the global colorectal cancer market share is segmented as:

• Digital Rectal Examination
• Faecal Occult Blood Test
• Flexible Sigmoidoscopy
• Colonoscopy
• Virtual Colonoscopy
• Double Contrast Barium Enema
• Others

Geographically, the colorectal cancer market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Technological advancement & innovation for screening colorectal cancer to lead the global colorectal cancer market share in North America.

On the basis of geography, North America is expected to dominate the global colorectal cancer market over forecast period. The colorectal cancer market is primarily driven by rising number of aging population in this region, and increasing research & development for new diagnostic methods and innovation of novel drug treatments by the manufacturers. Moreover, high expenditure on healthcare by the government would spur the market of colorectal cancer market in North America

However, Asia Pacific colorectal cancer is anticipated grow at a faster rate during the forecast period. Increasing number of aging population, availability of treatment drugs and diagnostics at an economic cost in countries such as China, India, and Japan are the major factor anticipated to govern the colorectal cancer market during upcoming years.

Key players in the global colorectal cancer market are:

• Amgen Inc.
• Bayer AG
• Boehringer Inghelheim Inc.
• Bristol-Myers Squibb
• Merck & Co.
• Seimens Healthcare
• Epigenomic AG
• Clinical Genomics
• Beckman Coulter
• Abbott Diagnostics
• EDP Biotech
• Genomic Tree
• Metabiomics Corporation